NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma
Relapsed/refractory Ewing sarcoma prognosis is dreadful, especially for recurrences within the first 2 years after initial diagnosis. It is obvious that there is an urgent need for novel treatment strategies for this dismal situation. NK-92 is an activated NK cell line with high cytotoxicity against...
Gespeichert in:
| Veröffentlicht in: | International cancer conference journal 2020-07, Vol.9 (3), p.137-140 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 140 |
|---|---|
| container_issue | 3 |
| container_start_page | 137 |
| container_title | International cancer conference journal |
| container_volume | 9 |
| creator | Yalcin, Koray Ovali, Ercument Ozdamarlar, Umut Celen, Suna Karasu, Gulsun Yesilipek, Akif Hazar, Volkan |
| description | Relapsed/refractory Ewing sarcoma prognosis is dreadful, especially for recurrences within the first 2 years after initial diagnosis. It is obvious that there is an urgent need for novel treatment strategies for this dismal situation. NK-92 is an activated NK cell line with high cytotoxicity against malignant cells. Here, we present a relapsed/refractory Ewing sarcoma case who had no response to conventional strategies and recieved intratumoral NK-92 cell injections. We observe that intratumoral injection of NK-92 is safe, has no toxicity and shows preliminary evidence of tumor response in relapsed/refractory Ewing Sarcoma. |
| doi_str_mv | 10.1007/s13691-020-00406-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7297928</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2919540606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-63f75a66119b2df3808451855d78ef5b63dadbab13e04ef4cb1cb0ed6bfa0bbd3</originalsourceid><addsrcrecordid>eNp9kE9PwkAQxTdGIwT5Ah5ME8-V2d12272YGAJqJHrR82b_FUpKW3eLhm_vIoh48TSTzJs3b34IXWK4wQDZyGPKOI6BQAyQAIvZCeoTzElMcU5Pj_oeGnq_BAjShEPOzlGPkjQnKc77aPr8FHMSaVtV60q6qFtYJ9tNVDQuaq0pZedKHTlbydZbM3K2cFJ3jdtEk8-ynkdeOt2s5AU6K2Tl7XBfB-htOnkdP8Szl_vH8d0s1pSnXcxokaWSMYy5IqagOeRJiJGmJsttkSpGjTRKKkwtJLZItMJagTVMFRKUMnSAbne-7VqtrNG27pysROvKlXQb0chS_J3U5ULMmw-REZ5xkgeD672Ba97X1ndi2axdHTILwjFPA0lgQUV2Ku0a78PThwsYxBa_2OEXgan4xi-2S1fH2Q4rP7CDgO4EPozquXW_t_-x_QJ4qJFa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2919540606</pqid></control><display><type>article</type><title>NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma</title><source>ProQuest Central (Alumni Edition)</source><source>SpringerNature Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>PubMed Central</source><source>ProQuest Central</source><creator>Yalcin, Koray ; Ovali, Ercument ; Ozdamarlar, Umut ; Celen, Suna ; Karasu, Gulsun ; Yesilipek, Akif ; Hazar, Volkan</creator><creatorcontrib>Yalcin, Koray ; Ovali, Ercument ; Ozdamarlar, Umut ; Celen, Suna ; Karasu, Gulsun ; Yesilipek, Akif ; Hazar, Volkan</creatorcontrib><description>Relapsed/refractory Ewing sarcoma prognosis is dreadful, especially for recurrences within the first 2 years after initial diagnosis. It is obvious that there is an urgent need for novel treatment strategies for this dismal situation. NK-92 is an activated NK cell line with high cytotoxicity against malignant cells. Here, we present a relapsed/refractory Ewing sarcoma case who had no response to conventional strategies and recieved intratumoral NK-92 cell injections. We observe that intratumoral injection of NK-92 is safe, has no toxicity and shows preliminary evidence of tumor response in relapsed/refractory Ewing Sarcoma.</description><identifier>ISSN: 2192-3183</identifier><identifier>EISSN: 2192-3183</identifier><identifier>DOI: 10.1007/s13691-020-00406-6</identifier><identifier>PMID: 32582518</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Biopsy ; Case Report ; Cell therapy ; Cells ; Chemotherapy ; Cytotoxicity ; Ewing's sarcoma ; Ewings sarcoma ; Immunotherapy ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastasis ; Natural killer cells ; Oncology ; Pediatrics ; Radiation therapy ; Surgical Oncology ; Tumors ; Ultrasonic imaging</subject><ispartof>International cancer conference journal, 2020-07, Vol.9 (3), p.137-140</ispartof><rights>The Japan Society of Clinical Oncology 2020</rights><rights>The Japan Society of Clinical Oncology 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-63f75a66119b2df3808451855d78ef5b63dadbab13e04ef4cb1cb0ed6bfa0bbd3</citedby><cites>FETCH-LOGICAL-c395t-63f75a66119b2df3808451855d78ef5b63dadbab13e04ef4cb1cb0ed6bfa0bbd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297928/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2919540606?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,21392,21393,27928,27929,33534,33748,41492,42561,43663,43809,51323,53795,53797,64389,64393,72473</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32582518$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yalcin, Koray</creatorcontrib><creatorcontrib>Ovali, Ercument</creatorcontrib><creatorcontrib>Ozdamarlar, Umut</creatorcontrib><creatorcontrib>Celen, Suna</creatorcontrib><creatorcontrib>Karasu, Gulsun</creatorcontrib><creatorcontrib>Yesilipek, Akif</creatorcontrib><creatorcontrib>Hazar, Volkan</creatorcontrib><title>NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma</title><title>International cancer conference journal</title><addtitle>Int Canc Conf J</addtitle><addtitle>Int Cancer Conf J</addtitle><description>Relapsed/refractory Ewing sarcoma prognosis is dreadful, especially for recurrences within the first 2 years after initial diagnosis. It is obvious that there is an urgent need for novel treatment strategies for this dismal situation. NK-92 is an activated NK cell line with high cytotoxicity against malignant cells. Here, we present a relapsed/refractory Ewing sarcoma case who had no response to conventional strategies and recieved intratumoral NK-92 cell injections. We observe that intratumoral injection of NK-92 is safe, has no toxicity and shows preliminary evidence of tumor response in relapsed/refractory Ewing Sarcoma.</description><subject>Biopsy</subject><subject>Case Report</subject><subject>Cell therapy</subject><subject>Cells</subject><subject>Chemotherapy</subject><subject>Cytotoxicity</subject><subject>Ewing's sarcoma</subject><subject>Ewings sarcoma</subject><subject>Immunotherapy</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Natural killer cells</subject><subject>Oncology</subject><subject>Pediatrics</subject><subject>Radiation therapy</subject><subject>Surgical Oncology</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><issn>2192-3183</issn><issn>2192-3183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kE9PwkAQxTdGIwT5Ah5ME8-V2d12272YGAJqJHrR82b_FUpKW3eLhm_vIoh48TSTzJs3b34IXWK4wQDZyGPKOI6BQAyQAIvZCeoTzElMcU5Pj_oeGnq_BAjShEPOzlGPkjQnKc77aPr8FHMSaVtV60q6qFtYJ9tNVDQuaq0pZedKHTlbydZbM3K2cFJ3jdtEk8-ynkdeOt2s5AU6K2Tl7XBfB-htOnkdP8Szl_vH8d0s1pSnXcxokaWSMYy5IqagOeRJiJGmJsttkSpGjTRKKkwtJLZItMJagTVMFRKUMnSAbne-7VqtrNG27pysROvKlXQb0chS_J3U5ULMmw-REZ5xkgeD672Ba97X1ndi2axdHTILwjFPA0lgQUV2Ku0a78PThwsYxBa_2OEXgan4xi-2S1fH2Q4rP7CDgO4EPozquXW_t_-x_QJ4qJFa</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Yalcin, Koray</creator><creator>Ovali, Ercument</creator><creator>Ozdamarlar, Umut</creator><creator>Celen, Suna</creator><creator>Karasu, Gulsun</creator><creator>Yesilipek, Akif</creator><creator>Hazar, Volkan</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20200701</creationdate><title>NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma</title><author>Yalcin, Koray ; Ovali, Ercument ; Ozdamarlar, Umut ; Celen, Suna ; Karasu, Gulsun ; Yesilipek, Akif ; Hazar, Volkan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-63f75a66119b2df3808451855d78ef5b63dadbab13e04ef4cb1cb0ed6bfa0bbd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biopsy</topic><topic>Case Report</topic><topic>Cell therapy</topic><topic>Cells</topic><topic>Chemotherapy</topic><topic>Cytotoxicity</topic><topic>Ewing's sarcoma</topic><topic>Ewings sarcoma</topic><topic>Immunotherapy</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Natural killer cells</topic><topic>Oncology</topic><topic>Pediatrics</topic><topic>Radiation therapy</topic><topic>Surgical Oncology</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yalcin, Koray</creatorcontrib><creatorcontrib>Ovali, Ercument</creatorcontrib><creatorcontrib>Ozdamarlar, Umut</creatorcontrib><creatorcontrib>Celen, Suna</creatorcontrib><creatorcontrib>Karasu, Gulsun</creatorcontrib><creatorcontrib>Yesilipek, Akif</creatorcontrib><creatorcontrib>Hazar, Volkan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International cancer conference journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yalcin, Koray</au><au>Ovali, Ercument</au><au>Ozdamarlar, Umut</au><au>Celen, Suna</au><au>Karasu, Gulsun</au><au>Yesilipek, Akif</au><au>Hazar, Volkan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma</atitle><jtitle>International cancer conference journal</jtitle><stitle>Int Canc Conf J</stitle><addtitle>Int Cancer Conf J</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>9</volume><issue>3</issue><spage>137</spage><epage>140</epage><pages>137-140</pages><issn>2192-3183</issn><eissn>2192-3183</eissn><abstract>Relapsed/refractory Ewing sarcoma prognosis is dreadful, especially for recurrences within the first 2 years after initial diagnosis. It is obvious that there is an urgent need for novel treatment strategies for this dismal situation. NK-92 is an activated NK cell line with high cytotoxicity against malignant cells. Here, we present a relapsed/refractory Ewing sarcoma case who had no response to conventional strategies and recieved intratumoral NK-92 cell injections. We observe that intratumoral injection of NK-92 is safe, has no toxicity and shows preliminary evidence of tumor response in relapsed/refractory Ewing Sarcoma.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>32582518</pmid><doi>10.1007/s13691-020-00406-6</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-3183 |
| ispartof | International cancer conference journal, 2020-07, Vol.9 (3), p.137-140 |
| issn | 2192-3183 2192-3183 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7297928 |
| source | ProQuest Central (Alumni Edition); SpringerNature Journals; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; PubMed Central; ProQuest Central |
| subjects | Biopsy Case Report Cell therapy Cells Chemotherapy Cytotoxicity Ewing's sarcoma Ewings sarcoma Immunotherapy Medical prognosis Medicine Medicine & Public Health Metastasis Natural killer cells Oncology Pediatrics Radiation therapy Surgical Oncology Tumors Ultrasonic imaging |
| title | NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T02%3A07%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NK-92%20cellular%20therapy%20for%20pediatric%20relapsed/refractory%20Ewing%20sarcoma&rft.jtitle=International%20cancer%20conference%20journal&rft.au=Yalcin,%20Koray&rft.date=2020-07-01&rft.volume=9&rft.issue=3&rft.spage=137&rft.epage=140&rft.pages=137-140&rft.issn=2192-3183&rft.eissn=2192-3183&rft_id=info:doi/10.1007/s13691-020-00406-6&rft_dat=%3Cproquest_pubme%3E2919540606%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2919540606&rft_id=info:pmid/32582518&rfr_iscdi=true |